Mitchell B. Diccianni

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Rajen Mody, Arlene Naranjo, Collin Van Ryn et al. · The Lancet Oncology · 2017 · 273 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · Clinical Cancer Research · 2021 · 216 citations · Full text

Life Sciences, Immunology, Oncology +17

Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group

Rajen Mody, Alice L. Yu, Arlene Naranjo et al. · Journal of Clinical Oncology · 2020 · 191 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

microRNA Signature and Expression of <i>Dicer</i> and <i>Drosha</i> Can Predict Prognosis and Delineate Risk Groups in Neuroblastoma

Ruey‐Jen Lin, You-Chin Lin, Jeremy Chen et al. · Cancer Research · 2010 · 184 citations · Full text

Medicine, Cancer Biology, Oncology +17

Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia.

Ayse Batova, Mitchell B. Diccianni, John Yu et al. · PubMed · 1997 · 149 citations

Life Sciences, Genetics, Oncology +17